2025 ACC/AHA Guideline on Treatment of Hypertension — What’s New in Management and Therapy

2025 ACC/AHA Guideline on Treatment of Hypertension — What’s New in Management and Therapy

Introduction

The 2025 American College of Cardiology / American Heart Association (ACC/AHA) Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults updates and replaces the 2017 guideline, providing clinicians with the latest evidence-based recommendations to improve outcomes in patients with hypertension. 

---

1. Goals of Treatment

Target Blood Pressure

• Universal goal of treatment is <130/80 mm Hg for most adults with hypertension. 

• Encouragement to achieve even lower systolic targets (e.g., <120 mm Hg) in selected individuals if tolerated. 

Risk-Guided Therapy

• Treatment decisions incorporate individualized cardiovascular risk estimation using the PREVENT risk calculator, replacing the Pooled Cohort Equation. This tool includes social determinants and improves risk prediction. 

---

2. When to Start Treatment

Lifestyle First, Then Medications

• Adults with BP ≥130/80 mm Hg and low cardiovascular risk (PREVENT <7.5%) should begin with 3–6 months of lifestyle modification. If goals are not met, initiate medication. 

Medications for Higher Risk or Stage 2 Hypertension

• Individuals with stage 1 hypertension and high risk (PREVENT ≥7.5%) or stage 2 hypertension (≥140/90 mm Hg) should start antihypertensive therapy promptly. 

---

3. Lifestyle Modification (Foundation of Management)

Key non-pharmacologic strategies emphasized in the guideline include:

• Dietary Approaches to Stop Hypertension (DASH) eating pattern with reduced sodium intake. 

• Weight reduction if overweight. 

• Increased physical activity, moderation of alcohol, and smoking cessation. 

• Routine home blood pressure monitoring to confirm diagnosis and track response. 

---

4. Pharmacologic Management

First-Line Medications

For most adults requiring drug therapy, the guideline supports initiation with one of the following:

• Thiazide-type diuretics

• ACE inhibitors or ARBs

• Long-acting dihydropyridine calcium channel blockers 

Single-Pill Combination Therapy

• In stage 2 hypertension (≥140/90 mm Hg), start with two first-line agents of different classes, ideally as a single-pill combination to improve adherence and efficacy. 

Sequential Add-on Therapy

• If targets are unmet, increase dose and/or add medications from different antihypertensive classes. 

Resistant Hypertension

• Evaluate for secondary causes (e.g., primary aldosteronism).

• If uncontrolled on optimal triple therapy (ACEi/ARB + CCB + thiazide), consider adding a mineralocorticoid receptor antagonist. 

Emerging Medications

• Newer agents like aprocitentan (Tryvio) are included for difficult-to-control hypertension in appropriate patients. 

---

5. Special Populations

Chronic Kidney Disease (CKD)

• Initiate therapy at ≥130/80 mm Hg with a goal of <130/80 mm Hg.

• ACE inhibitors or ARBs are preferred in patients with albuminuria to slow progression. 

Diabetes

• Early treatment with the same goals of <130/80 mm Hg is recommended. Goal may be titrated lower if tolerated. 

Pregnancy and Postpartum

• Treat chronic hypertension during pregnancy when BP ≥140/90 mm Hg to lower risks of complications.

• Postpartum monitoring and management are strongly emphasized. 

---

6. Cognitive Outcomes and Early Intervention

• New evidence suggests that early treatment of elevated blood pressure may reduce the risk of cognitive decline and dementia, reinforcing earlier intervention. 

---

7. Implementation Strategies

Team-Based Care and Home Monitoring

• Encouraged use of team-based models, patient education, and home BP monitoring to optimize control. 

---

Conclusion

The 2025 ACC/AHA hypertension guideline underscores earlier risk-based intervention, clear BP goals of <130/80 mm Hg, combined lifestyle and pharmacologic therapy, tailored drug selection for comorbidities, use of single-pill combinations, and personalized care incorporating new risk prediction tools such as PREVENT. 

---

References

1. Jones DW, et al. 2025 ACC/AHA Guideline… Hypertension. AHA/ACC/other writing committee. Hypertension. 2025. 

2. 2025 High Blood Pressure Guideline highlights and treatment recommendations. JACC & AHA reports. 

3. Early treatment, lifestyle, and pregnancy care in new 2025 guidelines. ACC/AHA press statements. 

4. Practical treatment initiation and medication strategies. Clinical summaries. 

Treatment of hypertension in the new 2025 guidelines ,  ACC/AHA guidelines